Tao Wu1, Yichen Chen2, Yantao Du2, Jin Tao3, Wei Li4, Zhong Zhou1, Zhuo Yang1. 1. Department of Cardiovascular, the Affiliated Hospital of Medical School of Ningbo University, Ningbo 315020, China. 2. Ningbo Institute of Medical Science, Ningbo 315020, China. 3. Zhejiang Pharmaceutical College, Ningbo 315000, China. 4. Ningbo Emergency Medical Center, Ningbo 315020, China.
Abstract
BACKGROUND: Circulating microRNA (miRNA) biomarkers have been extensively reported in cardiovascular diseases (CVDs). However, serum exosomal miRNA (exo-miRNA) as biomarker in patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain largely unexplored. We sought to investigate the potential of three types of serum exo-miRNAs as biomarkers for diagnosis in HFrEF patients who were admitted in hospital because of acute heart failure (AHF). METHODS: A total of 28 HFrEF patients hospitalized for AHF, including de novo AHF and acute decompensated HF, and 30 volunteers as control group (CG) from 2015 to 2017 were enrolled in this study. Serum exo-miRNAs were extracted and analyzed by NaNOZS-90, electron microscopy, and western blotting. Three types of serum exo-miRNAs (exo-miR-92b-5p, -192-5p, and -320a) were assessed by quantitative real time polymerase chain reaction (qRT-PCR). RESULTS: The particle size was confirmed as 40-150 nm using NaNOZS-90 and transmission electron microscopy. Exosomal biomarkers CD63 and Hsp70 were readily detected. The expression level of serum exo-miRNAs were transformed into log2-delta CT in the qPCR assay. The data showed that exo-miR-92b-5p was elevated in HFrEF patients compared with controls. Moreover, exo-miR-92b-5p was inversely correlated with the left ventricular fraction shortening (LVFS) and left ventricular ejection fraction (LVEF), whereas it was positively correlated with left atrial diameter (LAD), left ventricular diastolic diameters (LVDD) and systolic diameters (LVSD). A receiver operating characteristic (ROC) curve was generated for discrimination between HFrEF patients and controls based on exo-miR-92b-5p (P<0.001, sensitivity =71.4%, specificity =83.3%). CONCLUSIONS: Exo-miR-92b-5p levels in the serum may serve as a marker for HFrEF diagnosis.
BACKGROUND: Circulating microRNA (miRNA) biomarkers have been extensively reported in cardiovascular diseases (CVDs). However, serum exosomal miRNA (exo-miRNA) as biomarker in patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain largely unexplored. We sought to investigate the potential of three types of serum exo-miRNAs as biomarkers for diagnosis in HFrEF patients who were admitted in hospital because of acute heart failure (AHF). METHODS: A total of 28 HFrEF patients hospitalized for AHF, including de novo AHF and acute decompensated HF, and 30 volunteers as control group (CG) from 2015 to 2017 were enrolled in this study. Serum exo-miRNAs were extracted and analyzed by NaNOZS-90, electron microscopy, and western blotting. Three types of serum exo-miRNAs (exo-miR-92b-5p, -192-5p, and -320a) were assessed by quantitative real time polymerase chain reaction (qRT-PCR). RESULTS: The particle size was confirmed as 40-150 nm using NaNOZS-90 and transmission electron microscopy. Exosomal biomarkers CD63 and Hsp70 were readily detected. The expression level of serum exo-miRNAs were transformed into log2-delta CT in the qPCR assay. The data showed that exo-miR-92b-5p was elevated in HFrEF patients compared with controls. Moreover, exo-miR-92b-5p was inversely correlated with the left ventricular fraction shortening (LVFS) and left ventricular ejection fraction (LVEF), whereas it was positively correlated with left atrial diameter (LAD), left ventricular diastolic diameters (LVDD) and systolic diameters (LVSD). A receiver operating characteristic (ROC) curve was generated for discrimination between HFrEF patients and controls based on exo-miR-92b-5p (P<0.001, sensitivity =71.4%, specificity =83.3%). CONCLUSIONS: Exo-miR-92b-5p levels in the serum may serve as a marker for HFrEF diagnosis.
Authors: Maarten F Corsten; Robert Dennert; Sylvia Jochems; Tatiana Kuznetsova; Yvan Devaux; Leon Hofstra; Daniel R Wagner; Jan A Staessen; Stephane Heymans; Blanche Schroen Journal: Circ Cardiovasc Genet Date: 2010-10-04
Authors: Anke J Tijsen; Esther E Creemers; Perry D Moerland; Leon J de Windt; Allard C van der Wal; Wouter E Kok; Yigal M Pinto Journal: Circ Res Date: 2010-02-25 Impact factor: 17.367
Authors: Suresh Mathivanan; Justin W E Lim; Bow J Tauro; Hong Ji; Robert L Moritz; Richard J Simpson Journal: Mol Cell Proteomics Date: 2009-10-16 Impact factor: 5.911
Authors: Flavia Pichiorri; Sung-Suk Suh; Alberto Rocci; Luciana De Luca; Cristian Taccioli; Ramasamy Santhanam; Wenchao Zhou; Don M Benson; Craig Hofmainster; Hansjuerg Alder; Michela Garofalo; Gianpiero Di Leva; Stefano Volinia; Huey-Jen Lin; Danilo Perrotti; Michael Kuehl; Rami I Aqeilan; Antonio Palumbo; Carlo M Croce Journal: Cancer Cell Date: 2010-10-19 Impact factor: 31.743
Authors: Dongdong Zheng; Ming Huo; Bo Li; Weitie Wang; Hulin Piao; Yong Wang; Zhicheng Zhu; Dan Li; Tiance Wang; Kexiang Liu Journal: Front Cell Dev Biol Date: 2021-01-12
Authors: Evelyn M Templeton; Vicky A Cameron; John W Pickering; A Mark Richards; Anna P Pilbrow Journal: Heart Fail Rev Date: 2021-09 Impact factor: 4.214